Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PORCN | Q9H237 | 2/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.47 |
| ▸ | DAGLB | Q8NCG7 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | FPR1 | P21462 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | BRS3 | P32247 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15665299 | 0.81 | SMN1; SMN2 (0.52) | PORCNPIM1SMN1; SMN2 | |
| SCHEMBL29507440 | 0.81 | SMN1; SMN2 (0.52) | PORCNPIM1SMN1; SMN2 | |
| SCHEMBL15665079 | 0.81 | SMN1; SMN2 (0.52) | PORCNPIM1SMN1; SMN2 | |
| SCHEMBL6173007 | 0.80 | SMN1; SMN2 (0.46) | PORCNSMN1; SMN2BRS3 | |
| SCHEMBL13603832 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2BRS3 | |
| SCHEMBL8104378 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2BRS3 | |
| SCHEMBL7439477 | 0.76 | SMN1; SMN2 (0.41) | PIM1SMN1; SMN2BRS3 | |
| SCHEMBL6703929 | 0.75 | SMN1; SMN2 (0.50) | PORCNSMN1; SMN2BRS3CHRNA7 | |
| SCHEMBL7918841 | 0.75 | SMN1; SMN2 (0.50) | PORCNSMN1; SMN2BRS3CHRNA7 | |
| SCHEMBL3711892 | 0.74 | CNR2 (0.51) | SMN1; SMN2BRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002080920-A1 | ARYLACETAMIDO-KETOBENZOXAZOLE AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| US-20020156063-A1 | Arylacetamido-ketobenzoxazole as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2002080920-A1 | ARYLACETAMIDO-KETOBENZOXAZOLE AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156063-A1 | Arylacetamido-ketobenzoxazole as cysteine protease inhibitors | SERPINB1, SPINT2, PRSS1 | PORCN 1213/4885GHSR 4405/4885PIM1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.